CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
30 hedge funds and large institutions have $1.92M invested in CASI Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.7% less ownership
Funds ownership: 4.03% → 3.33% (-0.7%)
3% less funds holding
Funds holding: 31 → 30 (-1)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
87% less capital inflows, than outflows
Capital inflows: $67.7K | Capital outflows: $507K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$22.4K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$19.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15.3K |
| 4 |
Renaissance Technologies
New York
|
+$5.67K |
| 5 |
BlackRock Fund Advisors
San Francisco,
California
|
+$3.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$217K |
| 2 |
WSCM
Wellington Shields Capital Management
New York
|
-$141K |
| 3 |
CWM
Concert Wealth Management
San Jose,
California
|
-$45K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$25.4K |
| 5 |
MC
Moors & Cabot
Boston,
Massachusetts
|
-$20.3K |
CASI Hedge Fund Activity: Q4 2015 in Review
30 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2015, worth a combined $1.92M — down 26% from $2.59M a quarter earlier.
Fund positioning in CASI was balanced in Q4 2015: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 6 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $22.4K. The largest seller was Sabby Management, exiting entirely with an estimated $217K sold.
- 30 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2015, down from 31 in Q3 2015.
- Funds reported $1.92M of CASI Pharmaceuticals stock for Q4 2015, down 26% quarter-over-quarter.
- 5 funds opened new CASI Pharmaceuticals positions in Q4 2015 and 5 closed out, a net change of 0 holders.
- The largest CASI Pharmaceuticals buyer in Q4 2015 was Citadel Advisors, an estimated $22.4K added.
- The largest CASI Pharmaceuticals seller in Q4 2015 was Sabby Management, an estimated $217K sold.
Based on aggregated 13F filings for Q4 2015.